187 results about "ARDS" patented technology

The invention relates to the technical field of biomedical engineering, and discloses an acute respiratory distress syndrome mechanical ventilation adaptive adjustment control system, which comprises a data acquisition module, a signal preprocessing module, a physiological parameter calculation module, a prediction module, a decision and control logic module and the like. Wherein the prediction module predicts a dynamic lung compliance change trend by using a long short-term memory neural network model, and the decision and control logic module generates a ventilation parameter adjustment instruction according to a prediction result and a clinical safety rule. By adopting the technical scheme, the system overcomes the hysteresis of traditional feedback regulation, reduces the risk of breathing machine related lung injury, optimizes oxygenation and carbon dioxide removal efficiency, and provides an accurate, safe and individualized mechanical ventilation treatment scheme.

The invention discloses a prone position ARDS patient death risk prediction system based on interpretable machine learning, which constructs an interpretable machine learning prediction model based on clinical data of an ARDS patient before the ARDS patient receives prone position ventilation treatment, and is used for identifying high-death-risk crowds in an ICU (Intensive Care Unit). According to the method, an optimal prediction model is determined by performing preprocessing and correlation and collinearity screening on original variables, selecting key features by adopting Lasso regression and combining multi-model training and cross validation. On the basis, an SHAP method is introduced to explain a model decision basis, a column graph is constructed, visual expression of a risk assessment result is realized, and clinical understandability and practicability of the model are improved, so that auxiliary support is provided for precise treatment and resource allocation.

The invention discloses a risk early warning system based on enteral nutrition management of a patient, and belongs to the technical field of medical technology and biomedicine. A risk early warning system based on enteral nutrition management of a patient comprises a patient monitoring module, a score calculation module, a nutrition control module, an early warning notification module, a nutrition scheme adjustment module and a continuous observation and feedback module. The problems that in the prior art, symptoms of critical patients with the acute respiratory distress syndrome are not monitored in time, the regulation efficiency of enteral nutrition supply is low, errors are prone to occurring, and an early warning mechanism is incomplete are solved. By introducing a real-time monitoring and intelligent quantitative evaluation tool, an automatic regulation and control mechanism and multi-level early warning notification and detailed guidance, main problems existing in enteral nutrition management of the severe patient with the acute respiratory distress syndrome at present are effectively solved, and the rehabilitation process and the treatment effect of the patient are remarkably improved.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention relates to the technical field of bioinformatics, in particular to a method for typing acute respiratory distress syndrome biological subtypes. The method comprises the following steps: a) acquiring multi-omics data and carrying out standardized preprocessing; the multi-omics data comprises transcriptomics data, proteomics data and metabonomics data of a biological sample source; b) constructing a similarity network of each group by using a similarity fusion network (SNF), and obtaining a uniform sample similarity matrix through multi-group network fusion and iteration; multiple collaborative principal component analysis (MCIA) is adopted to carry out dimension reduction on multi-omics data so as to realize visualization of a clustering result; carrying out multi-omics joint discrimination modeling under the guidance of SNF clustering by using a data integration analysis (DIABLO) method so as to identify key feature variables; and carrying out biological subtype classification based on the clustering result of the steps.

The invention provides a synthesis method of a novel inhalable liposome and an application of the novel inhalable liposome in ARDS (arterial thrombosis syndrome) treatment, and the synthesis method comprises the following steps: firstly, mixing DSPE-PEG2K-TK-NHS and tocilizumab (TCZ: Tocilizumab) to form a lead compound DSPE-PEG2K-TK-TCZ; the preparation method comprises the following steps: dissolving DPPC, cholesterol, DSPE-TK-PEG2k and FG4592 in 5mL of chloroform, carrying out reduced pressure evaporation in a sample bottle to form a film, and adding 3mL of deionized water to prepare Lip-coated RF; and then stirring and incubating the DSPE-PEG2K-TK-TCZ and the Lip (at) RF, so as to form the Lip (at) RFT. As a functional nano-material with ultra-small size, good biocompatibility, excellent ROS removal capability and ROS responsive drug release, the nano-material is used for treating ARDS. The invention has the advantages that: the Lip-coated RFT relieves lung oxidative stress, inflammatory response, protein permeability and histological severity in the LPS-induced mouse ALI model. Therefore, Lip at RFT can be used as a new way for treating ARDS. Aerosol inhalation of Lip-coated RFT can effectively improve the severity of ARDS.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The invention discloses an application of sIL-2R alpha as a marker in a product for early prediction of acute respiratory distress syndrome. The product for early predicting the acute respiratory distress syndrome comprises a reagent or a medicine for detecting the expression level of sIL-2R alpha in a patient with the acute respiratory distress syndrome. The sIL-2R alpha is used as a biomarker, and experiments prove that the sIL-2R alpha level of the plasma of the ARDS patient is obviously higher than that of a patient without ARDS in the plasma of the ARDS patient. By detecting the sIL-2R alpha level of plasma or serum of an ARDS patient, the ARDS occurrence risk is predicted in an early stage, so that individualized intervention treatment is given, the occurrence rate of ARDS can be reduced, and the kit has important clinical application value for improving prognosis of the ARDS patient.

The invention discloses an intelligent diagnosis and typing method for pneumonia-related ARDS, and relates to the technical field of intelligent diagnosis and typing methods for ARDS, and the method comprises the steps: employing a data preprocessing method to carry out cleaning and standardization processing on pneumonia patient clinical data from MIMIC-IV and eICU databases, and obtaining a standardized data set; a correlation weight algorithm is adopted to screen 52 candidate variables in the standardized data set, and 18 key prediction factors are obtained; carrying out model training on the screened key predictive factors by adopting a machine learning stacking method to obtain a pneumonia-related ARDS diagnosis model; performing clustering analysis on the clinical data of the pneumonia-related ARDS patients by adopting a k-means clustering method, and dividing the patients into three clinical phenotypes based on nine input factors to obtain a subtype classification result; verifying a subtype classification result by adopting a random forest method to obtain a clinical subtype prediction model with high accuracy; and integrating and deploying the diagnosis model and the subtype classification model by adopting a webpage application program.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention discloses a biomarker combination for evaluating the illness state or prognosis of ARDS in the technical field of intensive care medicine, the biomarker combination comprises miR-21-5P and lncRNAgad7, and the biomarker combination can be used for predicting and evaluating the illness state or prognosis of ARDS so as to improve the accuracy of evaluating the illness state or prognosis of ARDS.

The invention discloses application of ubiquitin specific protease USP4 in treatment of acute lung injury / acute respiratory distress syndrome. The GEO database analysis finds that USP4 is increased in patients with acute respiratory distress syndrome; the expression level of USP4 is increased by stimulating human neutrophils in vitro with LPS, and experiments prove that the USP4 inhibitor Vialinin A can effectively treat acute lung injury and effectively improve the survival rate of mice; acute lung injury can be effectively relieved by using adenovirus to inhibit expression of USP4 in lung; the USP4 defect of the hematopoietic system can effectively relieve acute lung injury. The application of the USP4 serving as the target spot in screening the medicine for treating the acute lung injury or the acute respiratory distress syndrome is provided for the first time, a new target spot is provided for treating the acute lung injury or the acute respiratory distress syndrome, and a new treatment strategy is provided for clinical treatment.

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.

The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and / or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19 / cytokine release syndrome therapeutics-prophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-(R)-3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methylpropanoic acid—as a racemic mixture or separately, as the “R” enantiomer), compound 4 (3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-propanoic acid) and LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neo-natal / pediatric ARDS), including meconium aspiration syndrome and other disease states and conditions are also disclosed.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and / or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and / or SARS-CoV-2 / COVID-19, and influenza virus infections, optionally, H1N1 and / or H5N1.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The present disclosure relates to the detection of acute respiratory distress syndrome in a patient. Subjects of the present disclosure are a computer system, a method and a computer program product for detection of acute respiratory distress syndrome.

The invention discloses a vagus nerve electrical stimulation regulation method capable of relieving ARDS lung injury, and relates to the technical field of ARDS lung injury. In order to improve the therapeutic effect and prognosis of ARDS patients; comprising the following steps that 1, an ARDS animal model is established, and the animal model is constructed by instilling lipopolysaccharide (LPS) into the trachea; 2, after the ARDS model is established, separating and exposing the left vagus nerve of the animal; and 3, performing electrical stimulation on the left vagus nerve by using an electrical stimulation device, wherein the stimulation parameters comprise the voltage of 5V, the frequency of 5Hz and the pulse width of 2ms, and the stimulation lasts for 10 minutes. By implementing a vagus nerve electrical stimulation (VNS) regulation method, lung tissue pathological changes of an ARDS rat model can be remarkably improved, such as alveolar wall thickening, alveolar cavity stenosis and inflammatory cell infiltration, the lung injury score and the lung moisture-to-dry ratio are remarkably reduced, and the pulmonary edema condition is effectively relieved.

The application relates to the field of biological medicine, discloses application of a biomarker in an in-vitro auxiliary diagnosis product of sepsis complicated with ARDS, the biomarker is PDLIM1 in peripheral blood; further includes a detection kit and a use method thereof. The application first proposes that the PDLIM1 protein can be used as a biomarker to detect sepsis complicated with ARDS, compared with detection by means of a "combined judgment" method, the detection product can help medical staff to perform rapid detection, and in a ROC curve diagram, the AUC of PDLIM1 is greater than 0.8, the detection result is reliable, and the operation mode is relatively simple, so that the detection time is compressed, and the medical starting time is reduced.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention discloses a biomarker, a kit, a system, a method and application for acute respiratory syndrome (ARDS) inflammation phenotype typing. The biomarker combination is selected from any two or a combination of more than two of PLAUR, BSG, TNFRSF14, DFFA, IFNGR1, ENAH, LAIR1, NUB1, AGRN, LTBR, BTN3A2 and F2R, and the biomarker combination is a combination of any two or more of PLAUR, BSG, TNFRSF14, DFFA, IFNGR1, ENAH, LAIR1, NUB1, AGRN, LTBR, BTN3A2 and F2R. By detecting the expression level of the marker in serum of a subject and utilizing a machine learning classification model (such as XGBoost) for analysis, ARDS patients can be divided into three phenotypes of C1 (high inflammation and high injury), C2 (low inflammation repair) and C3 (intermediate). The typing method can accurately predict clinical outcomes such as the 90-day death rate of the patient and guide individualized application of glucocorticoid and PEEP ventilation strategies, and has important significance for achieving accurate treatment of ARDS.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

Methods for treating respiratory distress such as ARDS using foaming agent(s) (e.g., natural and / or synthetic surfactant(s)) and / or external energy (e.g., vibration, acoustic, etc.) and compositions and systems configured for performing the same.

The application discloses a lung inflammation lesion quantitative evaluation artificial intelligence model based on CT images and relates to the field of artificial intelligence models.The model comprises CT image preprocessing, self-supervised lesion segmentation and quantification, multi-modal joint pre-training coding and multi-task diagnosis and prognosis prediction module composition which are sequentially and communicatively connected, and realizes feature interaction through a unified feature embedding space.The model realizes self-supervised lesion segmentation and multi-dimensional quantification by adopting a three-dimensional generative reconstruction network, completes image-text feature fine-grained alignment through cross-modal contrast learning of an adversarial enhancement, and fuses multi-dimensional features.The model can complete multiple tasks such as ARDS diagnosis, non-invasive estimation of P / F ratio, severity grading and prognosis prediction in parallel, reduces dependence on artificial labeling, improves cross-center generalization capability and diagnosis precision, and provides a standardized intelligent tool for clinical evaluation of severe lung inflammation.

The invention provides application of a mitochondrial uncoupling agent BAM15 in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and the BAM15 can improve lung injury of an organism by maintaining dynamic balance of mitochondria, reducing neutrophil apoptosis delay, relieving oxidative stress and autophagy response and inhibiting a cGAS-STING signal channel. The mitochondrial uncoupling agent BAM15 is used for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), has the advantages of lower cytotoxicity, no interference on plasma membrane potential, wider treatment window and higher safety, and also has the advantages of delayed administration effectiveness, high treatment efficiency and the like, so that the mitochondrial uncoupling agent BAM15 can be applied to treatment of acute lung injury / acute respiratory distress syndrome (ALI / ARDS). The compound is a promising candidate drug for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and is beneficial to relieving mitochondrial injury, maintaining lung cell functions and reducing inflammatory response related to ALI / ARDS.